Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

151 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Retrospective evaluation of the clinical and radiographic risk factors associated with severe pulmonary hemorrhage in first-line advanced, unresectable non-small-cell lung cancer treated with Carboplatin and Paclitaxel plus bevacizumab.
Sandler AB, Schiller JH, Gray R, Dimery I, Brahmer J, Samant M, Wang LI, Johnson DH. Sandler AB, et al. Among authors: samant m. J Clin Oncol. 2009 Mar 20;27(9):1405-12. doi: 10.1200/JCO.2008.16.2412. Epub 2009 Feb 17. J Clin Oncol. 2009. PMID: 19224857 Free PMC article. Clinical Trial.
Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA.
Krop IE, Lin NU, Blackwell K, Guardino E, Huober J, Lu M, Miles D, Samant M, Welslau M, Diéras V. Krop IE, et al. Among authors: samant m. Ann Oncol. 2015 Jan;26(1):113-119. doi: 10.1093/annonc/mdu486. Epub 2014 Oct 29. Ann Oncol. 2015. PMID: 25355722 Free PMC article. Clinical Trial.
Corticosteroid use in patients with glioblastoma at first or second relapse treated with bevacizumab in the BRAIN study.
Vredenburgh JJ, Cloughesy T, Samant M, Prados M, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen R, Das A, Friedman HS. Vredenburgh JJ, et al. Among authors: samant m. Oncologist. 2010;15(12):1329-34. doi: 10.1634/theoncologist.2010-0105. Epub 2010 Dec 8. Oncologist. 2010. PMID: 21147867 Free PMC article. Clinical Trial.
Population pharmacokinetics of trastuzumab emtansine (T-DM1), a HER2-targeted antibody-drug conjugate, in patients with HER2-positive metastatic breast cancer: clinical implications of the effect of covariates.
Lu D, Girish S, Gao Y, Wang B, Yi JH, Guardino E, Samant M, Cobleigh M, Rimawi M, Conte P, Jin JY. Lu D, et al. Among authors: samant m. Cancer Chemother Pharmacol. 2014 Aug;74(2):399-410. doi: 10.1007/s00280-014-2500-2. Epub 2014 Jun 18. Cancer Chemother Pharmacol. 2014. PMID: 24939213 Free PMC article.
Exposure-response analyses of trastuzumab emtansine in patients with HER2-positive advanced breast cancer previously treated with trastuzumab and a taxane.
Li C, Wang B, Chen SC, Wada R, Lu D, Wang X, Polhamus D, French J, Vadhavkar S, Strasak A, Smitt M, Joshi A, Samant M, Quartino A, Jin J, Girish S. Li C, et al. Among authors: samant m. Cancer Chemother Pharmacol. 2017 Dec;80(6):1079-1090. doi: 10.1007/s00280-017-3440-4. Epub 2017 Oct 11. Cancer Chemother Pharmacol. 2017. PMID: 29022084 Clinical Trial.
151 results